Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1375 | Emotional Support Plan Wiki | 0.71 |
| drug141 | ASSIST Wiki | 0.71 |
| drug1148 | Daily Monitoring Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001321 | Autistic Disorder NIH | 0.43 |
| D000067877 | Autism Spectrum Disorder NIH | 0.38 |
| D002659 | Child Development Disorders, Pervasive NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000717 | Autism HPO | 0.43 |
| HP:0000729 | Autistic behavior HPO | 0.38 |
Navigate: Correlations HPO
There are 2 clinical trials
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly.
Description: 20 Moderate COVID-19 patients Moderate COVID-19 Positive testing by standard RT-PCR assay Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute No clinical signs indicative of Severe or Critical Illness Severity
Measure: Number of Participants with Moderate COVID-19: Time: Duration at least 28 daysDescription: 20 Moderate COVID-19 patients Positive testing COVID-19 by standard RT-PCR assay immediately COVID-19 nucleic acid testing, assessed by RT-PCR Assay Kit Rate of Positive COVID-19 nucleic acid must be 100%
Measure: Rate of Positive COVID-19 nucleic acid: Time: Duration at least 28 daysDescription: 0.1mg COVID-19 Spike-GM-CSF Protein 0.5 ml Lactated Ringer's Injection, USP 0.1mg / 0.5 ml COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
Measure: Concentration of Active Ingredient: Time: Duration at least 28 daysDescription: 20 Moderate COVID-19 patients 0.1mg / 0.5 ml COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection Intradermic Injection, ID Negative COVID-19 by standard RT-PCR assay after injection 2 weeks COVID-19 nucleic acid testing, assessed by RT-PCR Assay Kit Rate of Negative COVID-19 nucleic acid will be more than 80%
Measure: Rate of Negative COVID-19 nucleic acid Time: Duration at least 28 daysConducting an initial small, controlled clinical trial to assess for COVID-19 therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. Produce Antigen Presentation Memory to COVID-19 Specific Antigen. 4. Produce Trained Immunity to COVID-19 Specific Antigen. 5. Avoid Antibody-Dependent Enhancement (ADE) to COVID-19 Virus.
Description: Macrophage Migration Inhibitory Factor (MMIF), assessed by ELISA Sandwich Kit
Measure: Test Macrophage Migration Inhibitory Factor (MMIF) Time: Duration at least 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports